Metabonomic profiling of bladder cancer.
Early diagnosis and life-long surveillance are clinically important to improve the long-term survival of bladder cancer patients. Currently, a noninvasive biomarker that is as sensitive and specific as cystoscopy in detecting bladder tumors is lacking. Metabonomics is a complementary approach for identifying perturbed metabolic pathways in bladder cancer. Significant progress has been made using modern metabonomic techniques to characterize and distinguish bladder cancer patients from control subjects, identify marker metabolites, and shed insights on the disease biology and potential therapeutic targets. With its rapid development, metabonomics has the potential to impact the clinical management of bladder cancer patients in the future by revolutionizing the diagnosis and life-long surveillance strategies and stratifying patients for diagnostic, surgical, and therapeutic clinical trials. An introduction to metabonomics, typical metabonomic workflow, and critical evaluation of metabonomic investigations in identifying biomarkers for the diagnosis of bladder cancer are presented.
Department of Pharmacy, Faculty of Science, National University of Singapore , 18 Science Drive 4, Singapore 117543, Singapore.
Eric Chun Yong
EC
Chan
Kishore Kumar
KK
Pasikanti
Yanjun
Y
Hong
Paul C
PC
Ho
Ratha
R
Mahendran
Lata
L
Raman Nee Mani
Edmund
E
Chiong
Kesavan
K
Esuvaranathan
D006801:Humans; D055432:Metabolomics; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology
GC−MS; LC−MS; NMR; biomarker; bladder cancer; metabonomics